David W. Feigal, Jr.

Research Professor of the Arizona Biodesign Center at Arizona State University

David W. Feigal, Jr.

David W. Feigal, Jr.

Research Professor of the Arizona Biodesign Center at Arizona State University

Overview
RelSci Relationships

2961

Number of Boards

6

Birthday

1950

Age

71

Contact Data
Trying to get in touch with David W. Feigal, Jr.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals David W. Feigal, Jr. likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner at NDA Partners LLC

Relationship likelihood: Strong

Former Executive Chairman at CytoDyn, Inc.

Relationship likelihood: Strong

Chairman, Executive Board at NDA Partners LLC

Relationship likelihood: Strong

Expert Consultant at NDA Partners LLC

Relationship likelihood: Strong

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Founder at Bluewater International LLC

Relationship likelihood: Strong

Senior Vice President, Advanced Technology & Chief Technology Officer at Rockwell Automation, Inc.

Relationship likelihood: Strong

Founder at Wilkins Advisors, LLC

Relationship likelihood: Strong

Partner at Edward D. Jones & Co. LP (Investment Management)

Relationship likelihood: Strong

Co-Founder at Translate Bio, Inc.

Relationship likelihood: Strong

Paths to David W. Feigal, Jr.
Potential Connections via
Relationship Science
You
David W. Feigal, Jr.
Research Professor of the Arizona Biodesign Center at Arizona State University
Family Members
Spouse
Partner at NDA Partners LLC

NDA Partners LLC provides strategy consulting services. It also provides a comprehensive range of services across the product development life cycle for drugs, biologics, biosimilars, vaccines, generics, devices, combination products and diagnostics. The company was founded by Carl C. Peck and Earle Martin and is headquartered in Annapolis, MD.

Education
MPH

University of California Berkeley National rankings: In a National Research Council analysis of 212 doctoral programs at American universities, 48 Berkeley programs place among the top 10 nationwide. Faculty awards and honors: There are 8 Nobel Laureates, 32 MacArthur Fellows, and 4 Pulitzer Prize winners among the current faculty. History of UC Berkeley: Historical highlights, arranged by topic, following the campus's development — from UC's founding in 1868 to a turn-of-the-century building boom, a research explosion in the 1930s, the Free Speech Movement of the '60s, and Berkeley's key role today in science and technology revolutions. Timeline of discoveries and contributions by UC Berkeley scholars. Traditions of Cal: Who was the Angel of Death? What's with the "Big C" up there in the hills — and why is it sometimes green? Who wears Oski's jolly bear head and size 54 yellow sweater? Tours and webcams: Check out what's happening on Sproul Plaza, the campus's true heart. See stunning live views of the Bay Area from the Lawrence Hall of Science's perch in the Berkeley hills. Chancellor and administration: Information on Chancellor Robert Birgeneau, Executive Vice Chancellor and Provost George W. Breslauer, and how the university is organized. Organizational charts are included. UC System overview and links: On the campuses, laboratories, and medical centers that comprise UC's public educational system, as well as UC's K-12 partnerships, economic impact, and agriculture and environmental resources.

MD

A leader in the Biomedical Revolution, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies. Our close proximity to the resources of the university—including the Schools of Business, Law, Humanities and Sciences and Engineering—our seamless relationship with our affiliated adult and children’s hospitals and our ongoing associations with the entrepreneurial endeavors of Silicon Valley make us uniquely positioned to accelerate the pace at which new knowledge is turned into tangible health benefits.

Career History
Research Professor of the Arizona Biodesign Center
Current

Arizona State University (commonly referred to as ASU or Arizona State) is a national space-grant institution and public metropolitan research university located in the Phoenix Metropolitan Area of Arizona. ASU is the largest public university in the United States by enrollment. Founded in 1885 as the Tempe Normal School for the Arizona Territory, the school came under control of the Arizona Board of Regents in 1945 and was renamed Arizona State College. A 1958 statewide ballot measure gave the university its present name, making Arizona State one of the nation's newest public research universities.

Partner
2004 - Current

NDA Partners LLC provides strategy consulting services. It also provides a comprehensive range of services across the product development life cycle for drugs, biologics, biosimilars, vaccines, generics, devices, combination products and diagnostics. The company was founded by Carl C. Peck and Earle Martin and is headquartered in Annapolis, MD.

Special Advisor
Current

Gelesis, Inc. operates as a biotechnology company, which engages in the development of novel therapies to induce weight loss. It offers GELESIS100, a smart pill that is designed to treat the physiological symptoms of hunger without surgery, other invasive procedures or systemically absorbed drugs. The company was founded by Yishai Zohar in February 2006 and is headquartered in Boston, MA.

Boards & Committees
Member, Advisory Board
Current

Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA.

Member of the Advisory Board
Current

Bio Equity Capital focuses on investments in healthcare-focus special situations opportunities. The firm invests broadly across the healthcare sector including medical devices, specialty pharmaceuticals, biotechnology, diagnostics, healthcare information technology and services. They target opportunities to invest in mid- to later-stage companies and portfolios.Bio Equity Capital's investment may be structures as equity or debt, including distressed debt. The firm provides financing to equity and debt holders in both private and public healthcare companies through direct secondary transactions. Investments may be structured as a purchase alone or may be combined with a primary direct investment through which the firm acquires an equity interest. Bio Equity Capital typically transacts with venture capital and private equity firms and their limited partners, corporations, mutual funds, hedge funds, company founders and executives. The firm evaluates and acquires investment positions in both individual companies and portfolios of companies. In addition, in situations in which security holders seek to retain existing positions, but may experience value erosion in one or more of their investments as the result of follow-on-financings in which they are not participating, Bio Equity Capital can preserve the value with an annex fund structure.To be considered for a direct secondary investments, potential portfolio companies must eveident a catalyst such as: (1) a focus on recently raised funds (2) the need to provide liquidity to limited partners (3) the lack of or limited capital reserves for follow-on financing (4) the dissolution of a partnership (5) the need to reallocate capital and/or (6) the loss of key personnel.Bio Equity provides annex funding to allow investors to meet follow-on financing requirements for existing portfolio companies. Annex funding can protect the portfolio by providing capital to see existing investments through to liquidity and avoiding the detrimental implications of an inability to participate in future financings.Bio Equity Capital's investments in a single company typically average $1 million or more. The firm makes investments up to $250 million in healthcare-focused portfolios.

Director
2011 - 2011

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David W. Feigal, Jr.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David W. Feigal, Jr.'s profile does not indicate a business or promotional relationship of any kind between RelSci and David W. Feigal, Jr..